Leerink Partners Starts Patheon Holdings (PTHN) at Outperform

November 10, 2016 8:40 AM EST
Get Alerts PTHN Hot Sheet
Price: $26.22 +0.77%

Rating Summary:
    12 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade PTHN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners initiates coverage on Patheon Holdings (NYSE: PTHN) with a Outperform rating and a price target of $31.00.

Analyst Puneet Souda commented, "Patheon is poised to gain share in the highly fragmented contract development industry given its scale and end-to-end service offering for early-stage biotech to large-cap biopharma companies. We believe PTHN's scale will also continue to benefit it given the sticky nature of the business, generally high switching costs and regulatory burden associated with changing CDMOs. With current CDMO penetration ranging between only 26%-31% according to PTHN, compared to the 50% market penetration for CROs, we are inclined to believe that penetration for CDMOs including Patheon is only likely to grind higher. We remain confident that PTHN can deliver on an 8% revenue CAGR into 2019, but is also likely to lever acquisitions to drive growth even higher. During 2015, the company was involved in the development of 17 new drugs and more than 25% of the 100 top-selling drugs, which highlights in our view the value that large-cap biopharma places on a strategic development and a manufacturing partner such as Patheon."

For an analyst ratings summary and ratings history on Patheon Holdings click here. For more ratings news on Patheon Holdings click here.

Shares of Patheon Holdings closed at $28.10 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Add Your Comment